Summit Therapeutics (SMMT) Return on Capital Employed (2020 - 2024)

Summit Therapeutics has reported Return on Capital Employed for 5 years, with the latest figure at 52.87% in Q4 2024.

• For the quarter ending Q4 2024, Return on Capital Employed rose 26748.0% year-over-year to 52.87%; the trailing twelve-month figure through Dec 2024 stood at 52.87% (up 26748.0% YoY), and the FY2024 full-year result was 81.43%, up 6613.0% from the prior year.
• Return on Capital Employed for Q4 2024 stood at 52.87%, up from 54.11% in the prior quarter.
• The five-year high for Return on Capital Employed was 19.43% in Q4 2022, with the low at 519.99% in Q3 2023.
• Historically, Return on Capital Employed has averaged 128.79% across 5 years, with a median of 88.69% in 2020.
• Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 44848 bps — and 2024, when it surged 46589 bps.
• Summit Therapeutics' Return on Capital Employed stood at 88.96% in 2020, then decreased by 2 bps to 90.34% in 2021, then jumped by 78 bps to 19.43% in 2022, then slumped by 1549 bps to 320.35% in 2023, then surged by 83 bps to 52.87% in 2024.
• The last three Return on Capital Employed figures came in at 52.87% (Q4 2024), 54.11% (Q3 2024), and 133.2% (Q2 2024), per Business Quant data.